Keyphrases
Indoleamine 2,3-dioxygenase 1 (IDO1)
100%
Survivin
100%
Peptide Vaccine
100%
Metastatic Melanoma
100%
Temozolomide
100%
CD8+ T Cells
50%
CD4+
50%
Montanide
25%
Chemotherapy
25%
HLA-A2
25%
Vaccine-induced Immunity
25%
Vaccination
25%
Cancer Vaccination
25%
Phase II Study
25%
Tumor Regression
25%
Positron Emission Tomography-computed Tomography (PET-CT)
25%
Brain Metastases
25%
Immune Analysis
25%
Clinical Response
25%
Inhibitory Mechanism
25%
Clinical Activity
25%
Granulocyte Colony-stimulating Factor (G-CSF)
25%
Flow Cytometry
25%
Derived Peptide
25%
Specific Response
25%
CD4+ T Cells
25%
Disease Progression
25%
Nave
25%
ELISPOT
25%
Clinical Efficacy
25%
Melanoma
25%
Malignant Cells
25%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Melanoma
100%
Indoleamine 2,3 Dioxygenase
100%
Temozolomide
100%
Combination Vaccine
100%
Survivin
100%
Melanoma
50%
CD8 Antigen
50%
Tumor Regression
25%
Granulocyte Macrophage Colony Stimulating Factor
25%
Malignant Neoplasm
25%
Imiquimod
25%
Flow Cytometry
25%
Adjuvant
25%
Chemotherapy
25%
Polyethylene Terephthalate
25%
Disease Exacerbation
25%